Number of the records: 1  

The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia

  1. 1.
    0463915 - MBÚ 2017 RIV NL eng J - Journal Article
    Tomalová, Barbora - Šírová, Milada - Rossmann, Pavel - Pola, Robert - Strohalm, Jiří - Chytil, Petr - Černý, Viktor - Tomala, Jakub - Kabešová, Martina - Říhová, Blanka - Ulbrich, Karel - Etrych, Tomáš - Kovář, Marek
    The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
    Journal of Controlled Release. Roč. 223, 10 February (2016), s. 1-10. ISSN 0168-3659. E-ISSN 1873-4995
    R&D Projects: GA ČR(CZ) GAP301/11/0325; GA MŠMT(CZ) ED1.1.00/02.0109
    Institutional support: RVO:61388971 ; RVO:61389013
    Keywords : HPMA * Doxorubicin * Structure
    Subject RIV: EE - Microbiology, Virology; CD - Macromolecular Chemistry (UMCH-V)
    Impact factor: 7.786, year: 2016

    Polymer drug carriers that are based on N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers have been widely used in the development and synthesis of high-molecular-weight (HMW) drug delivery systems for cancer therapy. In this study, we compared linear (M-w similar to 27 kDa, Rh similar to 4 nm) and non-degradable star (M-w similar to 250 kDa, R-h similar to 13 nm) HPMA copolymer conjugates bearing anthracycline antibiotic doxorubicin (DOX) bound via pH-sensitive hydrazone bond. We determined the in vitro and in vivo toxicity of both conjugates and their maximum tolerated dose (MTD). We also compared their anti-tumour activity in mouse B-cell leukaemia (BCL1) and a mouse T-cell lymphoma (EL4) model. We found that MTD was higher for the linear conjugate (85 mg DOX/kg) and lower for the star conjugate (22.5 mg DOX/kg). An evaluation of the intestinal barrier integrity using FITC-dextran as a gut permeability tracer proved that no pathology was caused by the MTD of either conjugate. However, free DOX showed some damage to the gut barrier. The therapy of BCL1 leukaemia by both of the polymeric conjugates using the MTD or its fraction (i.e., equitoxic dosage) showed better results in the case of the star conjugate.
    Permanent Link: http://hdl.handle.net/11104/0263061

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.